Evidence map›Paper›PMID 30429496›Full record

Trial reportScientific reports2018

The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial.

Ming-Chia Hsieh, Wan-Hua Tsai, Yu-Pang Jheng, Shih-Li Su, Shu-Yi Wang, Chi-Chen Lin, Yi-Hsing Chen, Wen-Wei Chang

Erratum issuedOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 85 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 15 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 15 syntheses or guidelines pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Probiotic Supplementation and its Potential Benefits in Type 2 Diabetes: A Meta-analysis.Endocrine, metabolic & immune disorders drug targets · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Effect of Daily OralNutrients · 2021
    Trial
  17. Regulatory effects ofInternational journal of medical sciences · 2021
    Trial
  18. Review
  19. Review
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Ming-Chia HsiehGraduate Institute of Integrative Medicine, China Medical University, Taichung, 40402, Taiwan.
Wan-Hua TsaiResearch and Development Department, GenMont Biotech Incorporation, Tainan, 74144, Taiwan.
Yu-Pang JhengDivision of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan.
Shih-Li SuDivision of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan.
Shu-Yi WangDivision of Endocrinology and Metabolism, Department of Internal Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan.
Chi-Chen LinDepartment of Life Sciences, Institute of Biomedical Science, National Chung Hsing University, Taichung, 40249, Taiwan.
Yi-Hsing ChenResearch and Development Department, GenMont Biotech Incorporation, Tainan, 74144, Taiwan. ethan@genmont.com.tw.
Wen-Wei ChangDepartment of Biomedical Sciences, Chung Shan Medical University, Taichung, 40201, Taiwan. changww@csmu.edu.tw.ORCID http://orcid.org/0000-0003-2283-1377
Changhua Christian Hospital · TWGenMont Biotech (Taiwan) · TWChina Medical University · TWChung Shan Medical University Hospital · TWNational Chung Hsing University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Probiotics have been reported to ameliorate symptoms of type 2 diabetes mellitus (T2DM) in animal models and human studies. We previously demonstrated that oral administration of Lactobacillus reuteri ADR-3 reduced insulin resistance in high-fructose-fed (HFD) rats. In the present study, we first identified another L. reuteri strain, ADR-1, which displayed anti-diabetes activity that reduced the levels of serum HbA1c and cholesterol and that increased antioxidant proteins in HFD rats. We further performed a randomized, double-blinded, placebo-controlled trial with a total of 68 T2DM patients to examine the beneficial effects of oral consumption of L. reuteri strains ADR-1 and ADR-3 and to investigate the associated changes in intestinal flora using a quantitative PCR method to analyze 16 S rRNA in fecal specimens. Significant reductions in HbA1c and serum cholesterol were observed in participants in the live ADR-1 consumption group (n = 22) after 3 months of intake when compared with those in the placebo group (n = 22). Although there was no significant difference in the HbA1c serum level among participants who consumed heat-killed ADR-3 (n = 24), the systolic blood pressure and mean blood pressure were significantly decreased after 6 months of intake. There was no obvious change in serum inflammatory cytokines or antioxidant proteins in participants after intaking ADR-1 or ADR-3, except for a reduction in IL-1β in the ADR-3 consumption group after 6 months of intake. With the analysis of fecal microflora, we found that L. reuteri or Bifidobacterium spp. were significantly increased in the ADR-1 and ADR-3 consumption groups, respectively, after 6 months of intake. Interestingly, a significant reduction in HbA1c was observed in the ADR-1 and ADR-3 consumption participants who displayed at least an 8-fold increase in fecal L. reuteri. We also observed that there was a significantly positive correlation between Bifidobacterium spp. and Lactobacillus spp. in participants with increased levels of fecal L. reuteri. In the ADR-1 intake group, the fecal Lactobacillus spp. level displayed a positive correlation with Bifidobacterium spp. but was negatively correlated with Bacteroidetes. The total level of fecal L. reuteri in participants in the ADR-3 consumption group was positively correlated with Firmicutes. In conclusion, L. reuteri strains ADR-1 and ADR-3 have beneficial effects on T2DM patients, and the consumption of different strains of L. reuteri may influence changes in intestinal flora, which may lead to different outcomes after probiotic intake.

Indexed as

Limosilactobacillus reuteriAdultAgedAnimalsBifidobacteriumBlood PressureCholesterolDiabetes Mellitus, Type 2FemaleGastrointestinal MicrobiomeGlycated HemoglobinHumansMaleMiddle AgedProbioticsRatsCholesterolGlycated Hemoglobinhemoglobin A1c protein, human

Identifiers

PMID30429496
PMCPMC6235926
OpenAlexW2899856354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.